Progress in SPECT/CT Imaging of Prostate Cancer

Prostate cancer is the most common type of cancer (other than skin cancer) among men in the United States. Although prostate cancer is one of the few cancers that grow so slowly that it may never threaten the lives of some patients, it can be lethal once metastasized. Indium-111 capromab pendetide (ProstaScint®, Cytogen Corporation, Princeton, NJ) imaging is indicated for staging and recurrence detection of the disease, and is particularly useful to determine whether or not the disease has spread to distant metastatic sites. However, the interpretation of 111 In-capromab pendetide is challenging without correlated structural information mostly because the radiopharmaceutical demonstrates nonspecific uptake in the normal vasculature, bowel, bone marrow, and the prostate gland. We developed an improved method of imaging and localizing 111 In-Capromab pendetide using a SPECT/CT imaging system. The specific goals included: i) development and application of a novel iterative SPECT reconstruction algorithm that utilizes a priori information from coregistered CT; and ii) assessment of clinical impact of adding SPECT/CT for prostate cancer imaging with capromab pendetide utilizing the standard and novel reconstruction techniques. Patient imaging studies with capromab pendetide were performed from 1999 to 2004 using two different SPECT/CT scanners, a prototype SPECT/CT system and a commercial SPECT/CT system (Discovery VH, GE Healthcare, Waukesha, WI). SPECT projection data from both systems were reconstructed using an experimental iterative algorithm that compensates for both photon attenuation and collimator blurring. In addition, the data obtained from the commercial system were reconstructed with attenuation correction using an OSEM reconstruction supplied by the camera manufacturer for routine clinical interpretation. For 12 sets of patient data, SPECT images reconstructed using the experimental algorithm were interpreted separately and compared with interpretation of images obtained using the standard reconstruction technique. The experimental reconstruction algorithm improved spatial resolution, reduced streak artifacts, and yielded a better correlation with anatomic details of CT in comparison to conventional reconstruction methods (e.g., filtered back-projection or OSEM with attenuation correction only). Images produced with the experimental algorithm produced a subjective improvement in the confidence of interpretation for 11 of 12 studies. There were also changes in interpretations for 4 of 12 studies although the changes were not sufficient to alter prognosis or the patient treatment plan.

[1]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[2]  A.J. Da Silva,et al.  Absolute quantitation of myocardial activity in phantoms , 1998, 1998 IEEE Nuclear Science Symposium Conference Record. 1998 IEEE Nuclear Science Symposium and Medical Imaging Conference (Cat. No.98CH36255).

[3]  Mingshan Sun,et al.  Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  T. Turkington,et al.  ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. , 2005, AJR. American journal of roentgenology.

[5]  C. J. Schettino,et al.  Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. , 2004, AJR. American journal of roentgenology.

[6]  S. Vallabhajosula,et al.  Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer , 2005 .

[7]  M. Manyak,et al.  (111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY , 1998 .

[8]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[9]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[10]  N. Bander Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.

[11]  M. Roach,et al.  Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. , 1998, International journal of radiation oncology, biology, physics.

[12]  Sam S. Chang,et al.  The clinical role of prostate-specific membrane antigen (PSMA). , 2002, Urologic oncology.

[13]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Bruce H. Hasegawa,et al.  Absolute quantitation of myocardial activity in phantoms , 1998 .

[15]  Kenneth H. Wong,et al.  Calculation and validation of the use of effective attenuation coefficient for attenuation correction in In-111 SPECT. , 2005, Medical physics.

[16]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Renshaw,et al.  Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. , 2002, Urology.

[18]  T. Polascik,et al.  Capromab Pendetide imaging of prostate cancer. , 2000, Cancer biotherapy & radiopharmaceuticals.

[19]  N. Bander,et al.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.